NCT07059936 Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
| NCT ID | NCT07059936 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Condition | Hepatocellular Carcinoma (HCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2025-07 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2025-07 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CT imaging data and MR imaging data from liver cancer (hepatocellular carcinoma) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.
Eligibility Criteria
Inclusion Criteria: 1. Patients were treated for hepatocellular carcinoma in Wuhan Union Hospital from July 2025 to July 2026; 2. Aged \> 18 years old; 3. At least one CT scan or MR scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than liver cancer; 4. Unclear pathological diagnosis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07059936 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07059936 currently recruiting?
Yes, NCT07059936 is actively recruiting participants. Contact the research team at yanglian@hust.edu.cn for enrollment information.
Where is the NCT07059936 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07059936 clinical trial?
NCT07059936 is sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.